Maesopsin 4-O-β-D-glucoside, a natural compound isolated from the leaves of Artocarpus tonkinensis, inhibits proliferation and up-regulates HMOX1, SRXN1 and BCAS3 in acute myeloid leukemia

Journal of Chemotherapy

Volumn 23, Issue 3, 2011, Pages 150-157

  Pozzesi, N ^a   Pierangeli, S ^a   Vacca, C ^a   Falchi, L ^a   Pettorossi, V ^a   Martelli, M P ^a   Thuy, T T ^b   Ninh, P T ^b   Liberati, A M ^a   Riccardi, C ^a   Sung, T V ^b   Delfino, D V ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b INSTITUTE OF CHEMISTRY   (Viet Nam)

Author keywords

Acute myeloid leukemia; Artocarpus tonkinensis; BCAS3; HMOX1; Proliferation; SRXN1

Indexed keywords

ANTINEOPLASTIC AGENT; ARTOCARPUS TONKINENSIS EXTRACT; PLANT EXTRACT; TAT 2; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ARTOCARPUS TONKINENSIS; BCAS3 GENE; BREADFRUIT; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; CP2 GENE; CYTOKINE RELEASE; DNA MODIFICATION; DRUG ISOLATION; DRUG SCREENING; GENE; GENE EXPRESSION PROFILING; HMOX1 GENE; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; REAL TIME POLYMERASE CHAIN REACTION; SRXN1 GENE; UPREGULATION;

EID: 80052741094     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/joc.2011.23.3.150     Document Type: Article

References (25)

1. WHO Traditional Medicine Strategy 2002-2005. World Health Organization Geneva.
2. Zollman C, Vickers AJ. ABC of complementary Medicine London, BMJ Books. 2000.
3. Shanmugham LN, Castellani ML, Salini V, Falasca K, Vecchiet J, Conti P, et al. Relevance of lectins in human cell biology and immunology. Riv Biol 2006; 99:227-247.
4. Dang DTN, Eriste E, Liepinsh E, Trinh TT, Erlandsson-Harris H, Sil-lard R, et al. A novel anti-inflammatory compound, artonkin-4'-0-glucoside, from the leaves of Artocarpus tonkinensis suppresses experimentally in duced arthritis. 2009;69:110-118.
5. Uyama H. Artificial polymeric flavonoids: synthesis and applications. Macromol Biosci 2007;10:410-422.
6. Thuy TT, Kamperdick C, Ninh FT, Lien TP, Thao TT, Sung TV. Immunosuppressive auronol glycosides from Artocarpus tonkinensis. Phar-mazie 2004;59:297-300.
7. Ngoc DD, Catrina AL, Lundberg K, Harris HE, Ha NT, Anh PT, et al. Inhibition by Artocarpus tonkinensis of the development of collagen-in duced arthritis in rats. Scand J Immunol 2005;61:234-241.
8. Ley TJ, Mardis ER, Ding L, Fulton B, McLellan MD, Chen K, et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 2008;456:66-72.
9. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer sta tistics. CA Cancer J Clin 2008;58:71-96
10. Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood 2005;106:1154-1163.
11. Redaelli A, Lee JM, Stephens JM, Pashos CL. Epidemiology and clin ical burden of acute myeloid leukemia. Expert Rev Anticancer Ther 2003;3:695-710.
12. Appelbaum FR, Rowe JM, Radich J, Dick JE. Acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2009;62-86.
13. Buchner T, Hiddemann W, Berdel WE, Wormann B, Schoch C, Fonatsch C, et al. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for con solidation, and either prolonged maintenance by reduced montly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with the novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group. J Clin Oncol 2003;21:4496-4504.
14. Burnett AK, Goldstone AH, Stevens RM, Hann IM, Rees JK, Gray RG, et al. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties. Lancet 1998;351:700-708.
15. Wahlin A, Billstrom R, Bjor O, Ahlgren T, Hedenus M, Hoglund M, et al. Results of risk-adapted therapy in acute myeloid leukaemia. A long- term population-based follow-up study. Eur J Hematol 2009;83:99-107.
16. Romero AI, Thoren FB, Aurelius J, Askarieh G, Brune M, Hellstrand K. Post-consolidation immunotherapy with histamine dihydrochloride and interleukin-2 in AML. Scand J Immunol 2009;70:194-205.
17. Morris JC, Waldmann TA. Antibody-based therapy of leukaemia. Ex pert Rev Mol Med 2009;11:1-24.
18. Tsimberidou AM, Estey E, Wen S, Pierce S, Kantarjian H, Albitar M, Kurzrock R. The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes. Cancer 2008;113:1605-13.
19. Schimdt B, Ribnicky DM, Poulev A, Logendra S, Cefalu WT, Raskin I. A natural history of botanical therapeutics. Metabolism 2008;57 (7 Suppl l):S3-9.
20. Newman DJ, Cragg GM. Natural products from marine invertebrates and microbes as modulators of antitumor targets. Curr Drug Targets 2006;7:279-304.
21. Veljkovic J, Hansen U. Lineage-specific and ubiquitous biological roles of the mammalian transcription factor LSF. Gene 2004;343:23-40
22. Findlay VJ, Tapiero H, Townsend DM. Sulfiredoxin: a potential ther apeutic agent? Biomed Pharmacother 2005;59:374-379.
23. Mandal P, Pritchard MT, Nagy LE. Anti-inflammatory pathways and alcoholic liver disease: Role of an adiponectin/interleukin-10/heme oxyge- nase-1 pathway. World J Gastroenterol 2010;16: 1330-1336.
24. Miyazaki T, Kirino Y, Takeno M, Samukawa S, Hama M, Tanaka M, et al. Expression of heme oxygenase-1 in human leukemic cells and its reg ulation by transcriptional repressor Bachl. Cancer Sci 2010; Epub ahead of print.
25. Siva K, Venu P, Mahadevan A, Shankar SK, Inamdar MS. Human BCSA3 expression in embryonic stem cells and vascular precursors suggests a role in human embryogenesis and tumor angiogenesis. PLoS ONE 2007;2:e1202.